Curatis Holding AG CURN
SIX · Switzerland · Health Technology
CHF 17.75-0.90 (-4.83%)
Market closed· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
LIESTAL, Switzerland, September 21, 2026--Curatis Holding AG (SIX:CURN, "Curatis") reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufactur
LIESTAL, Switzerland, June 11, 2026--Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%.
We can readily understand why investors are attracted to unprofitable companies. By way of example, Curatis Holding...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.